UNLABELLED: Chronic liver disease is characterized by the liver enrichment of myeloid dendritic cells (DCs). To assess the role of disease on myelopoiesis, we utilized a systems biology approach to study development in liver-resident cells expressing stem cell marker CD34. In patients with endstage liver disease, liver CD34+ cells were comprised of two subsets, designated CD34+CD146+ and CD34+CD146-, and hematopoietic function was restricted to CD34+CD146- cells. Liver CD34 frequencies were reduced during nonalcoholic steatohepatitis (NASH) and chronic hepatitis C virus (HCV) compared to alcohol liver disease (ALD), and this reduction correlated with viral load in the HCV cohort. To better understand the relationship between liver CD34+CD146+ and CD34+CD146- subsets and any effects of disease on CD34 development, we used gene expression profiling and computational modeling to compare each subset during ALD and HCV. For CD34+CD146+ cells, increased expression of endothelial cell genes including von Willebrand factor, VE-cadherin, and eNOS were observed when compared to CD34+CD146- cells, and minimal effects of ALD and HCV diseases on gene expression were observed. Importantly for CD34+CD146- cells, chronic HCV was associated with a distinct "imprint" of programs related to cell cycle, DNA repair, chemotaxis, development, and activation, with an emphasis on myeloid and B lymphocyte lineages. This HCV signature was further translated in side-by-side analyses, where HCV CD34+CD146- cells demonstrated superior hematopoietic growth, colony formation, and diversification compared to ALD and NASH when cultured identically. Disease-associated effects on hematopoiesis were also evident by phenotypic alterations in the expression of CD14, HLA-DR, and CD16 by myeloid progeny cells. CONCLUSION: Etiology drives progenitor fate within diseased tissues. The liver may be a useful source of hematopoietic cells for therapy, or as therapeutic targets.
UNLABELLED: Chronic liver disease is characterized by the liver enrichment of myeloid dendritic cells (DCs). To assess the role of disease on myelopoiesis, we utilized a systems biology approach to study development in liver-resident cells expressing stem cell marker CD34. In patients with endstage liver disease, liver CD34+ cells were comprised of two subsets, designated CD34+CD146+ and CD34+CD146-, and hematopoietic function was restricted to CD34+CD146- cells. Liver CD34 frequencies were reduced during nonalcoholic steatohepatitis (NASH) and chronic hepatitis C virus (HCV) compared to alcohol liver disease (ALD), and this reduction correlated with viral load in the HCV cohort. To better understand the relationship between liver CD34+CD146+ and CD34+CD146- subsets and any effects of disease on CD34 development, we used gene expression profiling and computational modeling to compare each subset during ALD and HCV. For CD34+CD146+ cells, increased expression of endothelial cell genes including von Willebrand factor, VE-cadherin, and eNOS were observed when compared to CD34+CD146- cells, and minimal effects of ALD and HCV diseases on gene expression were observed. Importantly for CD34+CD146- cells, chronic HCV was associated with a distinct "imprint" of programs related to cell cycle, DNA repair, chemotaxis, development, and activation, with an emphasis on myeloid and B lymphocyte lineages. This HCV signature was further translated in side-by-side analyses, where HCVCD34+CD146- cells demonstrated superior hematopoietic growth, colony formation, and diversification compared to ALD and NASH when cultured identically. Disease-associated effects on hematopoiesis were also evident by phenotypic alterations in the expression of CD14, HLA-DR, and CD16 by myeloid progeny cells. CONCLUSION: Etiology drives progenitor fate within diseased tissues. The liver may be a useful source of hematopoietic cells for therapy, or as therapeutic targets.
Authors: Jeremy S Duffield; Stuart J Forbes; Christothea M Constandinou; Spike Clay; Marina Partolina; Srilatha Vuthoori; Shengji Wu; Richard Lang; John P Iredale Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: Sean R R Hall; Alexander Pedroza-Gonzalez; Qiuwei Pan; Hugo W Tilanus; Jeroen de Jonge; Gerard Wagemaker; Luc J W van der Laan Journal: Hepatology Date: 2013-04-08 Impact factor: 17.425
Authors: Evangelos Dalakas; Philip N Newsome; Shelagh Boyle; Rachael Brown; Anne Pryde; Shonna McCall; Peter C Hayes; Wendy A Bickmore; David J Harrison; John N Plevris Journal: Stem Cells Dev Date: 2010-09 Impact factor: 3.272
Authors: Victoria M Velazquez; Huiming Hon; Chris Ibegbu; Stuart J Knechtle; Allan D Kirk; Arash Grakoui Journal: Hepatology Date: 2012-12 Impact factor: 17.425
Authors: Xiao Qi Wang; Chung Mau Lo; Lin Chen; Cindy K Y Cheung; Zhen Fan Yang; Yong Xiong Chen; Michael N Ng; Wan Ching Yu; Xiaoyan Ming; Wu Zhang; David W Y Ho; See Ching Chan; Sheung Tat Fan Journal: Hepatology Date: 2012-10 Impact factor: 17.425
Authors: Mehul S Suthar; Margaret M Brassil; Gabriele Blahnik; Aimee McMillan; Hilario J Ramos; Sean C Proll; Sarah E Belisle; Michael G Katze; Michael Gale Journal: PLoS Pathog Date: 2013-02-07 Impact factor: 6.823
Authors: Dana Tedesco; Manoj Thapa; Sanjeev Gumber; Elizabeth J Elrod; Khalidur Rahman; Chris C Ibegbu; Joseph F Magliocca; Andrew B Adams; Frank Anania; Arash Grakoui Journal: Hepatology Date: 2016-12-19 Impact factor: 17.425
Authors: Dana Tedesco; Manoj Thapa; Chui Yoke Chin; Yong Ge; Minghao Gong; Jing Li; Sanjeev Gumber; Patrick Speck; Elizabeth J Elrod; Eileen M Burd; William H Kitchens; Joseph F Magliocca; Andrew B Adams; David S Weiss; Mansour Mohamadzadeh; Arash Grakoui Journal: Gastroenterology Date: 2018-02-15 Impact factor: 22.682